Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

The relationship between 22q11.2 deletion syndrome and Parkinson's disease

FY 2013-14

Summary
Recently, two diseases that had been thought to be completely different from each other have been found to have a very close relationship: Parkinson’s disease (PD) and 22q11.2 deletion syndrome (22q11.2DS; also known as DiGeorge syndrome or velocardiofacial syndrome). PD is a neurodegenerative disorder that affects 1% of people over the age of 65. It is caused by death of neurons in a part of the brain known as the substantia nigra and produces tremor and rigidity in the patient. 22q11.2DS occurs when we are born with a segment of DNA on chromosome 22 that gets mistakenly deleted. This causes numerous abnormalities, including congenital heart defects, developmental delay, and mental illness. We have discovered that PD occurs at a rate that is 90 times higher than expected in patients with 22q11.2DS. Our overall aim is to study these two diseases and to discover the underlying molecular and genetic link between them. More specifically, the purpose of our upcoming work is to study how 22q11.2DS increases one’s risk of developing PD. By understanding the basis by which this happens, we can better comprehend how PD develops, discover new genetic risk factors for PD, and ultimately develop more effective means to prevent and treat PD. Our working theory is that there is a gene on the deleted segment of DNA on chromosome 22 that is involved in the development of PD and we plan on testing this idea in humans and in an animal model of 22q11.2DS. In human patients, we will examine post-mortem brain tissue under the microscope to discover how pathological changes develop. One potential trigger involved in the development of PD is inflammation in the brain. Much research in the last decade has shown that in PD, inflammation is abundant as evidenced by certain cells (microglia) involved in the inflammatory process being present in large numbers. In our samples, we plan on studying them further by assessing the presence and absence of microglia and comparing these results to normal human subjects. We will also identify whether or not proteins involved in inflammation such as TNF, IL-1B, and IFN are increased in these brain samples. In order to conduct experiments to better understand the cause of the increased susceptibility to PD, we will be using a mouse model of 22q11.2DS. Unlike humans, these mice do not spontaneously develop PD. We believe that a stimulus such as inflammation is needed in order to trigger the development of PD, which may mimic what happens in humans. Therefore, we will be treating these mice with an agent that produces inflammation and then assessing for behavioural changes (which correlates with the tremor and rigidity seen in human PD) and examine the brain for microscopic changes. Finally, by doing experiments on individual cells in culture, we hope to determine which specific gene or protein is responsible for the changes that we see. This research is significant in many ways. PD is a common debilitating illness that leads to significant morbidity not only on the patients it afflicts but also on their caregivers as well. Several risk genes for PD have already been identified over the past two decades and our research will add to this literature by possibly identifying a previously unknown risk gene on chromosome 22. This willl give us a better understanding of how PD develops and in the future, this may lead to strategies that can more effectively prevent and/or treat PD.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
312045
Name
Gao Andrew
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The relationship between 22q11.2 deletion syndrome and Parkinson's disease
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
22q11.2 Deletion Syndrome; Digeorge Syndrome; Mouse Model; Neurodegeneration; Neuroinflammation; Parkinson'S Disease
Abstract
Recently, two diseases that had been thought to be completely different from each other have been found to have a very close relationship: Parkinson’s disease (PD) and 22q11.2 deletion syndrome (22q11.2DS; also known as DiGeorge syndrome or velocardiofacial syndrome). PD is a neurodegenerative disorder that affects 1% of people over the age of 65. It is caused by death of neurons in a part of the brain known as the substantia nigra and produces tremor and rigidity in the patient. 22q11.2DS occurs when we are born with a segment of DNA on chromosome 22 that gets mistakenly deleted. This causes numerous abnormalities, including congenital heart defects, developmental delay, and mental illness. We have discovered that PD occurs at a rate that is 90 times higher than expected in patients with 22q11.2DS. Our overall aim is to study these two diseases and to discover the underlying molecular and genetic link between them. More specifically, the purpose of our upcoming work is to study how 22q11.2DS increases one’s risk of developing PD. By understanding the basis by which this happens, we can better comprehend how PD develops, discover new genetic risk factors for PD, and ultimately develop more effective means to prevent and treat PD. Our working theory is that there is a gene on the deleted segment of DNA on chromosome 22 that is involved in the development of PD and we plan on testing this idea in humans and in an animal model of 22q11.2DS. In human patients, we will examine post-mortem brain tissue under the microscope to discover how pathological changes develop. One potential trigger involved in the development of PD is inflammation in the brain. Much research in the last decade has shown that in PD, inflammation is abundant as evidenced by certain cells (microglia) involved in the inflammatory process being present in large numbers. In our samples, we plan on studying them further by assessing the presence and absence of microglia and comparing these results to normal human subjects. We will also identify whether or not proteins involved in inflammation such as TNF, IL-1B, and IFN are increased in these brain samples. In order to conduct experiments to better understand the cause of the increased susceptibility to PD, we will be using a mouse model of 22q11.2DS. Unlike humans, these mice do not spontaneously develop PD. We believe that a stimulus such as inflammation is needed in order to trigger the development of PD, which may mimic what happens in humans. Therefore, we will be treating these mice with an agent that produces inflammation and then assessing for behavioural changes (which correlates with the tremor and rigidity seen in human PD) and examine the brain for microscopic changes. Finally, by doing experiments on individual cells in culture, we hope to determine which specific gene or protein is responsible for the changes that we see. This research is significant in many ways. PD is a common debilitating illness that leads to significant morbidity not only on the patients it afflicts but also on their caregivers as well. Several risk genes for PD have already been identified over the past two decades and our research will add to this literature by possibly identifying a previously unknown risk gene on chromosome 22. This willl give us a better understanding of how PD develops and in the future, this may lead to strategies that can more effectively prevent and/or treat PD.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gao, Andrew
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~